Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?

Autor: Jingyang Luan, Taiping Zhang, Zhe Cao, Wenhao Luo, Lianfang Zheng, Gang Yang, Jiangdong Qiu, Ying Zhang, Yupei Zhao, Mengyu Feng, Fangyu Zhao, Lei You, Yueze Liu
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Drug
Oncology
Cancer Research
medicine.medical_specialty
Pancreatic ductal adenocarcinoma
RNA
Untranslated
Therapeutic effectiveness
media_common.quotation_subject
pancreatic cancer
Apoptosis
Review
chemistry
Deoxycytidine
lcsh:RC254-282
Histone Deacetylases
03 medical and health sciences
0302 clinical medicine
Pharmacotherapy
prevention
Pancreatic cancer
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Tumor Microenvironment
Animals
Humans
Radiology
Nuclear Medicine and imaging
media_common
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Gemcitabine
drug therapy
Pancreatic Neoplasms
030104 developmental biology
Drug Resistance
Neoplasm
030220 oncology & carcinogenesis
Neoplastic Stem Cells
Cancer Prevention
metabolism
medicine.drug
Carcinoma
Pancreatic Ductal
Signal Transduction
Zdroj: Cancer Medicine, Vol 8, Iss 14, Pp 6403-6413 (2019)
Cancer Medicine
ISSN: 2045-7634
Popis: Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide. Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma (PDAC) and numerous potential mechanisms have been demonstrated but much remains to be understood. To overcome the existing limitations in PC treatment, newer approaches targeting intrinsic or acquired mechanisms have been found to improve drug therapeutic effectiveness in PC patients. Here, we provide an update of the most recent findings and their implications for clinicians, and attempt to summarize the various aspects of different individualized novel therapies for PC that could most benefit metastatic PDAC patients.
The latest treatment schemes based on various mechanisms of drug resistance in pancreatic cancer; 2. The advantages and disadvantages of those novel therapies and enumerated feasible methods to improve the efficacy of chemo‐therapies which are hopefully applied to clinics.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje